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Abstract
Background: Valve thrombosis – either biological or mechanical – is proved to increase patient’s morbidity and
mortality. No consensus exist on the best management in such cases.
Case presentation: We report the case of a 69-year-old man presenting with a late thrombosis of a transcatheter
aortic valve who was medically managed until he acutely worsened, developing myocardial ischemia and cardiogenic
shock.
Conclusion: This unlucky case raises a word of caution about the safety of a reactive management.
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Background
Prosthetic valve thrombosis is known to carry relevant
morbidity and mortality. Little is known about its occur-
rence after transcatheter aortic valve replacement
(TAVR); all the information we have are derived from
case reports and relatively small series of patients [1].
The current postoperative management suggests dual
antiplatelet therapy (DAPT) to reduce the risk of valve
thrombosis, even if more and more evidences reveal the
potential superiority of oral anticoagulation [2] A more
serious issue regards the appropriate management once
the valve thrombosis has occurred.
Case presentation
A 69-year-old man was referred to our Emergency
Department for resting dyspnea after 2 months progres-
sive shortness of breath, 2 years after transcatheter aortic
valve replacement (TAVR).
In 1994 he underwent aortic valve replacement with a
23mm Biocor™ valve (St. Jude, MN, USA) for native
valve endocarditis. Eleven years later (2015) he was
re-operated for structural valve deterioration. In that oc-
casion – due to the presence of extreme calcification of
the aortic annulus and root – we had to replace the
prosthesis with a 23 mm Edwards Sapien 3 transcatheter
valve (Edwards Lifesciences, Irvine, CA) under direct
view, as previously described [3].
The patient revealed anticoagulants discontinuation
due to excessive bleeding after surgery for a chordoma
of the nose within the last 2 months (he was on anti-
coagulant after an episode of atrial fibrillation). He took
Aspirin 100 mg/day with a good compliance. He had no
history of hyper-coagulation state or previous docu-
mented thrombosis.
The transthoracic echocardiogram showed increased
trans-valvular gradients (mean left ventricular outflow
tract/aorta gradient of 62 mmHg with 0,43cm2 of valvu-
lar area) and ipo-echogenic images evocative of
intra-valvular thrombosis. A thoracic computed tomog-
raphy (CT) confirmed the presence of valvular throm-
bosis (Fig. 1) in the presence of diseased-free coronary
anatomy. After discussion in the Heart Team setting it
was decided to attempt systemic anticoagulation with
heparin to achieve dissolution of the thrombus. After 1
week of systemic anticoagulation a control CT did not
show any evidence of improvement, so we planned a
surgical re-intervention. The day before the scheduled
surgery the patient suddenly experienced thoracic pain
and electrocardiographic signs of myocardial ischemia.
An urgent coronary angiography was performed while
* Correspondence: marcogennari.md@gmail.com
1Centro Cardiologico Monzino, IRCCS, Via Parea 4, 20138 Milan, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gennari et al. Journal of Cardiothoracic Surgery          (2018) 13:126 
https://doi.org/10.1186/s13019-018-0816-4
Fig. 1 a The echocardiogram was suggestive for valve thrombosis (arrow). b & c. The finding was confirmed on thoracic computed tomography (arrows)
Fig. 2 Intraoperative images. The new transcatheter valve deployed under direct view (arrow)
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the clinical and hemodynamic state worsened. He had a
cardiac arrest during the procedure; an immediate
cardio-pulmonary resuscitation (CPR) was performed
while a peripheral extracorporeal membrane oxygen-
ation (ECMO) support was instituted and the patient
transferred into the operating room for an emergent
surgery.
After cardioplegic cardiac arrest and transverse aortot-
omy the thrombosed transcatheter valve was excised
and a new 23mm Edwards Sapien 3 valve was deployed
in an off-label fashion under direct view with good echo-
cardiographic result (Fig. 2). The valve thrombosis was
confirmed once excised (Fig. 3).
Unfortunately he developed an incoercible cardiogenic
and septic shock and finally died on the 10th postopera-
tive day.
Discussion
Prosthetic valve thrombosis (PVT) accounts for any
thrombus formation attached to or near a prosthetic
valve that is not caused by infection and determining
some degree of valve obstruction and dysfunction and
that carries significant morbidity and mortality to the
patient.
Some degree of reduced leaflet motion is a detected in
10 to 15% of TAVR patients and generally resolves after
anticoagulation therapy. [4] Although currently either
the North American and European Society of Cardiology
suggest DAPT following TAVR procedures, more and
more clinical evidences seem to propose a more appro-
priate management by oral anticoagulants after trans-
catheter aortic valve replacement.
No consensus exists regarding the best treatment op-
tion once the thrombus has developed.
In this case the biggest challenge was balancing a po-
tential life–threatening condition caused by valve
thrombosis and its initial dysfunction and the extremely
elevated surgical risk due to the third cardiac operation
after surgical implantation of a transcatheter valve due
to porcelain aortic root and annulus. Thus, the first-line
we choose was trying to manage the patient conserva-
tively with systemic heparinization and close clinical and
instrumental monitoring.
In this case the localized aggressive tumor and the
relevant postoperative bleeding may have impaired the
hemostatic status of the patient, shifting it toward a
pro-coagulant one.
We speculate that the transcatheter valve forced
against the stiff aortic ring of the previous transcatheter
valve and the rigidity and narrowing of the degenerated
homograft has caused a progressive thrombosis occurred
within the stented portion of the valve towards the leaf-
lets once the hemostasis perturbation occurred leading
to the catastrophic consequence.
Conclusion
From this unlucky case a word of caution arises about the
medical management of such TAVR population; although
a single case report does not provide wider conclusion we
believe that a very close monitoring of the clinical ad mor-
phologic valve features are mandatory while the surgical
option still remains valid once an early evidence of no im-
provement after adequate anticoagulation therapy.
Abbreviations
CPR: Cardio-pulmonary resuscitation; DAPT: Dual antiplatelet therapy;
ECMO: Extracorporeal membrane oxygenation; NOACs: The novel anti
coagulants; PVT: Prosthetic valve thrombosis; TAVR: Transcatheter aortic valve
replacement
Acknowledgements
Not applicable.
Funding
We state no funding for this paper.
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Authors’ contributions
MG: clinical management, idea and writing; GP: supervision; MP: supervision;
FA: clinical management; AA: data collection; MA: supervisor. All authors read
and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
We have obtained the consent for anonymous publication of data and
figures from the relatives of the patient.
Competing interests
Marco Gennari MD is Consultant to Medtronic.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Fig. 3 Intraoperative image of the excised transcatheter valve with
the adherent thrombus (arrow)
Gennari et al. Journal of Cardiothoracic Surgery          (2018) 13:126 Page 3 of 4
Author details
1Centro Cardiologico Monzino, IRCCS, Via Parea 4, 20138 Milan, Italy.
2Department of Cardiovascular Sciences and Community Health, University
of Milan, Milan, Italy.
Received: 27 September 2018 Accepted: 3 December 2018
References
1. Cota L, Stabile E, Agrusta M, Sorropago G, Pucciarelli A, et al. Bioprostheses
"thrombosis" after transcatheter aortic valve replacement. J Am Coll Cardiol.
2013;61(7):789–91.
2. Chakravarty T, Søndergaard L, Friedman J, De Backer O, Berman D, et al.
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic
aortic valves: an observational study. Lancet. 2017;S0140–6736(17):30757–2.
3. Tessari C, D'Onofrio A, Guglielmi C, Gerosa G. Sapien XT implantation under
direct vision as a bail-out procedure in case of hostile aortic root: a
reasonable alternative for stentless bioprosthesis reoperation. J Thorac
Cardiovasc Surg. 2013;145(3):e36–8.
4. Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, et al.
Guidelines for reporting mortality and morbidity after cardiac valve
interventions. J Thorac Cardiovasc Surg. 2008;135(4):732–8.
Gennari et al. Journal of Cardiothoracic Surgery          (2018) 13:126 Page 4 of 4
